Low-dose trimethoprim-sulfamethoxazole for prophylaxis of <i>Pneumocystis jirovecii</i> pneumonia in HIV-uninfected patients: a systematic review and meta-analysis.

ABSTRACT:

Background

Trimethoprim-sulfamethoxazole (TMP-SMX) is the recommended first-line prophylactic agent against Pneumocystis jirovecii pneumonia (PJP). However, the standard regimen is often discontinued due to its drug-associated adverse events (AEs), especially in immunocompromised patients without HIV infection. Therefore, we aimed to investigate the efficacy and safety of a low-dose regimen of TMP-SMX against PJP prophylaxis in patients without infection.

Methods

We searched PubMed, Embase, Wanfang, China National Knowledge Infrastructure, Web of Science, and the Cochrane database for relevant articles from inception to 15 October 2024. Studies were included if they reported the safety and efficacy of using TMP-SMX in PJP prophylaxis in patients without HIV infection.

SUBMITTER: Huang HB 

PROVIDER: S-EPMC12303816 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature